Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second Wave in 2021 – A Preliminary Report from a Single Hospital

Ritu Arora, Ruchi Goel, Samreen Khanam, Sumit Kumar, Shalin Shah, Sonam Singh, Mohit Chhabra, Ravi Meher, Nita Khurana, Tanu Sagar, Suresh Kumar, Sandeep Garg, Jyoti Kumar, Sonal Saxena, Rashmi Pant

1Department of Ophthalmology, Guru Nanak Eye Centre, Maulana Azad Medical College, New Delhi, India; 2Department of Otorhinolaryngology, Maulana Azad Medical College, New Delhi, India; 3Department of Pathology, Maulana Azad Medical College, New Delhi, India; 4Department of Microbiology, Maulana Azad Medical College, New Delhi, India; 5Department of Medicine, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India; 6Department of Radiodiagnosis, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India; 7Society for Health Education and Allied Research, New Delhi, India

Purpose: To list the clinico-epidemiological profile and possible risk factors of COVID-19 associated rhino-orbital-cerebral mucormycosis (CA-ROCM) patients presenting to a COVID dedicated hospital during the second wave of COVID-19 in India.

Patients and Methods: A cross-sectional, single-center study was done on 60 cases of probable CA-ROCM based on clinical features and supportive diagnostic nasal endoscopic findings and/or radiologic findings. Patients with recent or active COVID-19 were included. The demographic profile, clinical features, possible risk factors and diagnostic workup (microbiological, pathological and radiological) were analysed to identify the triggering factors for CA-ROCM.

Results: The age of patients ranged from 29 to 75 years and male–female ratio was 3:1. The duration between the first positive COVID report and onset of CA-ROCM was 0 to 47 days. Forty-nine (81.66%) patients had a recent COVID infection and 11 (18.33%) had active COVID infection at presentation. Thirty-five patients (58%) had ocular/orbital involvement at presentation. In the affected eye, 10 had no perception of light and in the rest visual acuity ranged from log MAR 0 to +1.5. Ocular manifestations were ptosis (29), ophthalmoplegia (23), periocular tenderness and edema (33), proptosis (14), black discoloration of eyelids (3), facial palsy (3), endophthalmitis (4), retinal artery occlusion (8), disc edema (4) and disc pallor (5). Twenty-two (25%) patients had neither received steroids nor oxygen. Thirty patients (50%) were managed with oxygen while 38 patients (63.3%) with systemic steroids.

Conclusion: SARS-CoV-2 variant with accompanying glycaemic dysregulation was found to be the triggering factor for the epidemic of CA-ROCM.

Keywords: COVID-19 treatment, CA-ROCM, orbital apex syndrome, ophthalmoplegia, retinal arterial occlusion, COVID-19 associated rhino-orbital-cerebral mucormycosis

Introduction

India’s resurgence in COVID infections began around mid-March 2021 and increased rapidly, reaching a peak of more than 414,000 daily cases on May 6, 2021. The daily death toll rose to 3754 by May 9, 2021. While the onslaught continued, another invisible foe entered the arena in the form of COVID-19 associated Mucormycosis (CA-ROCM). CA-ROCM had been recognized during the first wave in India. By June 7, 2021, a deluge of 28,252
Mucormycosis cases was reported, 86% having history of COVID-19. Interestingly, the Indian SARS CoV-2 genomic consortium found the delta variant (B.1.617.2) to be responsible for >90% COVID cases in May 2021 in comparison to <5% before January 2021.

CA-ROCM has a world-wide distribution, the major chunk being contributed by India. In a systematic review of 101 cases of mucormycosis with COVID-19, 82 were from India and the remaining 19 from USA (9), Iran (3), UK (1), France (1), Italy (1), Brazil (1), Turkey (1), Mexico (1) and Austria (1). Recently, 15 more cases from 5 centers in India from April to September 2020 and 2826 cases from 98 centers between January 1, 2020 and May 26, 2021 in India have been reported, reflecting the magnitude of the disease burden. Most of the reports of ROCM include the time period over 2020 till May 2021. There exists only one report of 70 cases of ROCM exclusively in the severe, devastating second wave of COVID 19 starting in April 2021.

A preliminary study was thus designed to document the clinical along with microbiological, pathological, radiological features and possible risks to gain an insight into the triggering factors for the swarm of COVID-19 associated ROCM and to formulate guidelines for prevention of the disease.

Materials and Methods
A cross-sectional study was conducted on CA-ROCM patients, admitted in the single largest COVID dedicated hospital in India. After obtaining institutional ethical committee clearance (F.I/IEC/MAMC/(84/02/2021/No.396), the hospital patient data repository was screened for patient files with diagnosis of probable ROCM and COVID-19 between May 15 and June 5, 2021. Written informed consent was taken and probable ROCM patients with documented COVID-19 infection from March 2021 onwards were included in the study. The study complies with the Declaration of Helsinki and all organs were donated voluntarily with written informed consent, in accordance with Declaration of Istanbul. A patient with clinical features suggestive of ROCM, supported by nasal endoscopy findings or imaging was diagnosed as probable ROCM. Patients with incomplete records or those, unable to give consent were excluded from the study. A detailed data collection sheet was formulated for the information to be collected from the hospital records based on demographic profile, vaccination status, date of COVID-19 diagnosis, date of onset of CA-ROCM symptoms, clinical features of ROCM, associated co-morbidities, glycosylated hemoglobin (HbA1c) status, treatment received for COVID-19, nasal endoscopy findings, microbiological, pathological and radiological details, medical treatment initiated for ROCM, surgical planning and/or execution.

Details of recent COVID-19 presentation and severity were retrieved from the available documents with the patients. ROCM was staged per the proposed code mucor guidelines for staging. The diagnosis of COVID-19 was based on documented positive reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen report of naso- oropharyngeal swab. Patients recovered from COVID-19 infection three months prior and currently RT-PCR negative for SARS-CoV2 were designated as recent COVID-19. The time limit of three months was taken as per the widely accepted definition of post-acute COVID 19 syndrome. Active COVID-19 cases were defined as patients who were laboratory confirmed for SARS-CoV-2 (by rapid antigen or RT-PCR) at presentation. The severity of COVID-19 was based on the prescribed Indian government guidelines. Mild COVID-19 cases were to be managed in home isolation with symptomatic treatment and oral Ivermectin (200 mcg/kg once a day for 3–5 days). Patients with moderate to severe disease were hospitalized. They were managed with oxygen therapy, anticoagulation, awake proning, intravenous (IV) methylprednisolone 0.5 to 1 mg/kg or IV Dexamethasone 0.1 to 0.2 mg/kg (moderate COVID) and IV methylprednisolone 1 to 2 mg/kg in two divided doses or IV Dexamethasone 0.2 to 0.4 mg/kg (severe COVID) usually for a duration of 5 to 10 days. The duration of administration of steroids was to be reviewed and modified as per the clinical response. They were to be initiated or switched to oral route if stable and/or improving. Antibiotics were prescribed only on suspicion of bacterial infection.

Statistical Analysis
Baseline characteristics of the patients were described using frequencies and percentages for the categorical variables and median and interquartile range for the continuous variables such as age, duration of diabetes, value of HbA1c and the lag between laboratory confirmation of COVID-19 and detection of ROCM. Duration from laboratory confirmation of COVID-19 and detection of ROCM was dichotomized at the median value as early and late detection of ROCM. Its relationship was explored with potential risk factors such as severity of COVID-19,
presence of diabetes, vaccination status, systemic steroid use, oxygen administration and presenting clinical features using logistic regression model. The regression (effect) estimates were reported as risk ratios (RR) and 95% confidence intervals. RR was converted to percentages to report increase or decrease in risk of early onset for each of the independent variables mentioned above. The percentage change in risk was calculated as \((\text{estimated RR}-1) \times 100\) if RR > 1 and \((1-\text{estimated RR}) \times 100\) if RR < 1. Since sample size for regression was small, p-values ≤ 0.1 were considered significant.

**Results**

Out of the 65 cases of CA-ROCM admitted during the study period, five were excluded owing to incomplete data. The demographic profile and risk factors for ROCM are given in Table 1. The median age was 57 years, ranging from 29 to 75 years, with male–female ratio being 3:1. Eleven patients had active COVID-19 and 49 were recent COVID-19 cases. None of the cases had received both the doses of COVID-19 vaccine (Covaxin, Bharat Biotech/ Covishield, AstraZeneca, Serum institute of India).

Thirty-eight patients were hospitalized for COVID management earlier and three of them were treated in intensive care units (ICU). Twenty-two patients were treated in home isolation and had not received steroids or oxygen. Corticosteroids were administered in 38 cases, oral (prednisolone/methylprednisolone) in 11 and parenteral (methylprednisolone/ dexamethasone) in 27. The cumulative prednisolone-equivalent dose ranged from 5.7 mg/day to 128.7 mg/day and the total dose being >600mg in only 6 patients. Thirty patients had received oxygen for an average duration of 10.8 ± 3.58 days. Pre-existing diabetes was found in 49 cases, duration ranging from 1 to 25 years, and newly diagnosed diabetes was observed in 10 cases. The average HbA1c levels were

| Risk Factor                      | Number of Cases/Median | Percentage/Interquartile Range |
|----------------------------------|------------------------|-------------------------------|
| **Age (years)**                  | 57                     | 51.5–62                       |
| **Gender**                       |                        |                               |
| Male                             | 45                     | 75                            |
| Female                           | 15                     | 25                            |
| **COVID Vaccination status**     |                        |                               |
| No dose                          | 53                     | 88.3                          |
| First dose                       | 7                      | 11.7                          |
| **Severity of COVID infection**  |                        |                               |
| Mild                             | 26                     | 45.6                          |
| Moderate                         | 28                     | 49.1                          |
| Severe                           | 3                      | 5.3                           |
| **Oxygen**                       |                        |                               |
| Not given                        | 30                     | 50                            |
| Given                            | 30                     | 50                            |
| **Place of receiving treatment** |                        |                               |
| Home quarantine                  | 22                     | 36.6                          |
| Health facility                  | 38                     | 63.3                          |
| **Steroid administration**       |                        |                               |
| None                             | 22                     | 36.7                          |
| Oral                             | 11                     | 18.3                          |
| Intravenous                      | 27                     | 45                            |
| **Tocilizumab administration**   | 2                      | 3.3                           |
| **Diabetes Mellitus**            | 59                     | 98.3                          |
| Newly diagnosed                  | 10                     | 16.6                          |
| Known diabetics                  | 49                     | 81.6                          |
| Diabetic ketoacidosis            | 3                      | 5                             |
| Duration of diabetes (years)     | 5                      | 2.5–7                         |
| HbA1c                            | 9.25                   | 8.3–12.6                      |
| **Other Co-morbid conditions**   |                        |                               |
| Hypertension                     | 14                     | 23.3                          |
| Coronary artery disease          | 6                      | 10                            |
| Thyroid dysfunction              | 4                      | 6.6                           |
| Chronic kidney disease           | 2                      | 3.3                           |
| Stroke                           | 1                      | 1.67                          |

(Continued)
10.31± 2.59% (ranging from 6.1 to 14.6%) and >8% in 88.1% of the diabetic patients. The lone non diabetic patient had undergone liver transplantation and was on cumulative prednisolone equivalent dose of 15mg/day, oral mycophenolate mofetil 500 mg twice a day and oral Tacrolimus 1mg twice a day. Besides diabetes, hypertension was the second most common co-morbidity.

Table 2 Staging and Clinical Features of ROCM Patients

| Number of Cases | Percentage of Cases (Out of 60) |
|-----------------|---------------------------------|
| ROCM staging    |                                 |
| 1               | 0                               |
| 2               | 25                              |
| 3               | 29                              |
| 4               | 6                               |
| First symptom of ROCM |                        |
| Facial pain     | 35                              |
| Facial swelling | 12                              |
| Decreased vision| 4                               |
| Black/blood-stained nasal discharge | 3 |
| Diplopia        | 2                               |
| Headache        | 1                               |
| Dental pain     | 1                               |
| Facial numbness | 1                               |
| Nasal blockage  | 1                               |
| Ptotis          | 1                               |
| Laterality of ocular disease at presentation |                        |
| Left            | 11                              |
| Right           | 24                              |
| Visual acuity in the affected eye at presentation |                          |
| Log Mar 0 to +1.5 | 50                          |
| Loss of light perception | 10 |
| Ocular signs and symptoms related to Mucormycosis at presentation |                      |
| Total cases     | 35                              |
| Ptotis          | 29                              |
| Total ophthalmoplegia | 18                      |
| Periocular tenderness | 17                            |
| Periocular edema | 16                              |
| Proptosis       | 14                              |
| Diminution of vision | 12                         |
| Complete loss of vision | 10                           |
| Central/branch retinal artery occlusion | 8                          |
| Partial ophthalmoplegia | 5                           |
| Disc pallor     | 5                               |
| Disc edema      | 4                               |
| Endophthalmitis with severe hypotony | 4               |
| Black discoloration of eyelids | 3                   |
| Facial palsy    | 3                               |
| Diplopia        | 2                               |

Nasal signs and symptoms at presentation

Table 2 (Continued).

| Percentage of Cases (Out of 60) |
|---------------------------------|
| Number of Cases |
| Total cases | 49 | 81.7 |
| Crusting     | 36 | 60  |
| Epistaxis    | 18 | 30  |
| Nasal blockage | 17   |
| Black discharge | 12   |
| Nasal ulcer/eschar | 1   |

Facial signs and symptoms at presentation

| Percentage of Cases (Out of 60) |
|---------------------------------|
| Number of Cases |
| Total cases | 39 | 65  |
| Facial pain | 35 | 58.3 |
| Infra-orbital anaesthesia | 27 |
| Facial swelling | 17 |
| Supra-orbital hypoesthesia | 4 |
| Facial discoloration | 3 |

Involvement of oral cavity at presentation

| Percentage of Cases (Out of 60) |
|---------------------------------|
| Number of Cases |
| Total cases | 3 | 5 |
| Dental pain | 2 | 3 |
| Palate perforation | 1 | 1.67 |

Central nervous system signs and symptoms at presentation

| Percentage of Cases (Out of 60) |
|---------------------------------|
| Number of Cases |
| Total cases | 6 | 10 |
| Altered sensorium | 3 |
| Hemiplegia      | 2 | 3 |
| Headache        | 1 | 1.67 |

10.31± 2.59% (ranging from 6.1 to 14.6%) and >8% in 88.1% of the diabetic patients. The lone non diabetic patient had undergone liver transplantation and was on cumulative prednisolone equivalent dose of 15mg/day, oral mycophenolate mofetil 500 mg twice a day and oral Tacrolimus 1mg twice a day. Besides diabetes, hypertension was the second most common co-morbidity.

Staging of ROCM patients and their clinical features are presented in Table 2. Facial pain was the commonest first symptom of ROCM patients. Thirty-five of the 60 patients (58%) belonged to Stage 3 and 4 and had unilateral orbital involvement, ptosis being the commonest ocular manifestation (Figure 1).

The median duration between the first laboratory confirmation of COVID-19 and detection of CA-ROCM was 17 days, ranging from 0 to 47 days, cases detected prior to 17 days were labeled as detected early and the remaining as late. Detection of ROCM was delayed by an average of 7 days (95% CI: -13.51,-0.54) in patients vaccinated with...
first COVID-19 dose as compared to those who were not vaccinated (p=0.03) and an average of 5 days (95% CI: -9.09, -0.84) in those who had been administered oxygen during COVID-19 treatment as compared to those who had not been given the oxygen (p=0.02). Early detection by 4.7 days (95% CI: 0.35, 9.08) (p=0.03) was observed in cases having facial signs and symptoms on presentation. Presence of any ocular sign/symptom, ptosis and complete loss of vision were also associated with early detection by 2.7 days (95% CI: -1.61, 7.06) (p=0.3), 2.26 days (95% CI: -2.03, 6.55) (p=0.3) and 2.5 days (95% CI: -3.19, 8.35) (p=0.37) respectively, though statistically insignificant. The chances of early detection of ROCM decreased by 35% (p=0.1) in moderate COVID-19 infection (Table 3). Higher chance of early detection by 64% (p=0.06) in patients presenting with ocular sign or symptom and by 42% (p=0.01) in patients who had not received systemic steroids was observed.

Initial radiological work up comprised of contrast enhanced computerized tomography (CECT). Magnetic resonance imaging (MRI) was performed in suspected orbital apex lesion or intracranial spread. Thirty-five patients had undergone imaging and the remaining were scheduled in the next few days. Patchy enhancement of the orbital fat (30/35), orbital apex lesion (10/35), thickening of extraocular muscles (14/35), intraocular exudation (4/35) and subperiosteal abscess (2/35) were observed in the orbital scans (Figure 2). Of the 6 patients in stage 4, 3 had focal cavernous sinus involvement and additionally 3 had diffuse cavernous sinus thrombosis with brain infarction at varying sites.

Direct microscopy of the diagnostic nasal endoscopy swab of the 60 cases, using KOH mount showed non/pauci septate, irregular, broad, ribbon-like hyphae with wide angle non-dichotomous branching in 19 cases, 8 of which grew Mucorales and in 2, both Aspergillus species and Mucorales were isolated on culture (Figure 3). Histopathology of 37 cases was available. Tissue invasion of hyphae consistent morphologically with Mucor were seen in 22, 3 being mixed infection with Candida (1) and Aspergillus species (2). There was presence of acute suppurative cellular reaction (2), necrosis with no cellular reaction (16) and granulomatous reaction in 4 samples.
All the patients were treated with IV amphotericin B liposomal (Amphonex-Bharat serums and vaccines Ltd.) (IV 5mg/kg daily). Functional endoscopic sinus surgery (FESS) was performed in 10 patients. In 2 cases FESS was combined with maxillectomy and orbital exenteration. Transcutaneous retrobulbar amphotericin B injection (Amphomul-Bharat serums and vaccines Ltd.)(1mL of 3.5mg/mL) daily for 3 days was given in 6 eyes with stage 3 ROCM with diffuse or apical enhancement on contrast enhanced MRI. The remaining 48 patients were planned for radical sinus debridement.

Discussion

Mucormycosis, is known to be associated with malignant hematological disease, severe neutropenia, uncontrolled diabetes mellitus, iron overload, major trauma, prolonged use of corticosteroids and IV drug abuse. ROCM, a spectrum of limited sino-nasal, rhino-orbital and rhino-orbital-cerebral disease, often has underlying uncontrolled diabetes and diabetic ketoacidosis (DKA). Of late, increasing numbers of CA-ROCM have been encountered. The vulnerability of COVID-19 patients to mucormycosis has been attributed to presence of diabetes, use of immunosuppressive therapy in moderate to severe cases, ICU stay and mechanical ventilation. The median age of affliction of CA-ROCM patients has been reported as 44.5, 51.9, 52 and 55 years with male predilection of 60%, 71%, 66% and 79% respectively. The demographic profile in our series was similar to previous reports, the median age being 57 with 75% male preponderance. Factors cited for the skewed male:female ratio are greater exposure to fungal spores due to prolonged outdoor exposure in males and protective role of oestrogens in females.

| Table 3 Association Between Early Detection of ROCM with Various Risk Factors |
|------------------------------------------|---------|---------|---------|
| Risk Factor                         | Relative Risk | 95% CI   | p-value |
|----------------------------------|-------------|---------|---------|
| Age (years)                       | 0.99        | (0.98, 1.02) | 0.92   |
| Gender                            |             |         |         |
| Male (Reference)                  | 1           |         |         |
| Female                            | 0.96        | (0.56, 1.65) | 0.88   |
| COVID Vaccination status          |             |         |         |
| No dose (Reference)               | 1           |         |         |
| First dose                        | 0.24        | (0.04, 1.47) | 0.1    |
| Severity of COVID infection       |             |         |         |
| Mild (Reference)                  | 1           |         |         |
| Moderate                          | 0.65        | (0.3932, 1.0927) | 0.11  |
| Severe                            | 0.51        | (0.1004, 2.5879) | 0.42  |
| Oxygen given                      |             |         |         |
| Not given                         | 1.54        | (0.9509, 2.4890) | 0.07  |
| Given (Reference)                 | 1           |         |         |
| Place of treatment                |             |         |         |
| Home quarantine                   | 1.23        | (0.7822, 1.9439) | 0.37  |
| Health facility (Reference)       | 1           |         |         |
| Systemic steroids                 |             |         |         |
| Taken (Reference)                 | 1           |         |         |
| Not taken                         | 1.42        | (0.93, 2.24) | 0.1    |
| Duration of Diabetes (years)      |             |         |         |
| <5 (Reference)                    | 1           |         |         |
| ≥5                                | 1.03        | (0.6501, 1.6369) | 0.90  |
| Laterality of ocular disease      |             |         |         |
| None (Reference)                  | 1           |         |         |
| Left                              | 0.8920      | (0.6148, 1.2943) | 0.55  |
| Right                             | 1.1061      | (0.8259, 1.4813) | 0.50  |
| Visual acuity                     |             |         |         |
| Log MAR 0 to +1.5                 | 1.35        | (0.8285, 2.1871) | 0.23  |
| Loss of vision                    |             |         |         |
| Ocular symptoms                   |             |         |         |
| No (Reference)                    | 1           |         |         |
| Yes                               | 1.64        | (0.9608, 2.8091) | 0.06  |
| Ophthalmoplegia                   |             |         |         |
| No (Reference)                    | 1           |         |         |
| Yes                               | 1.25        | (0.7968, 1.9609) | 0.33  |

(Continued)
In our study, all except one patient were diabetic, 88.1% having HbA1c >8%. Three of these patients suffered from DKA. In 31 cases of ROCM, reported during the first wave in India over 6 months, 30 had uncontrolled diabetes, 6 were newly diagnosed and average value of HbA1c was 7.57%. In a multicentric Indian study comprising of 2826 CA-ROCM patients from both waves, 2194 cases were diabetic, 972 being either uncontrolled diabetes or DKA. In another retrospective Indian study on CA-ROCM exclusively during the second wave, from April 1, 2021 to June 1, 2021, out of the 70 cases, 49 cases were diabetic, 5 were recently diagnosed and 9 had concomitant DKA. Poor glycaemic control possibly resulted from cytokine storm and direct injury to the pancreatic beta cells in the backdrop of limited access to routine diabetes care because of lockdown.

Systemic corticosteroids are recommended in moderate and severe COVID-19 cases. Similar to observation by Ramaswami et al regarding indiscriminate use of steroids, 4 mild COVID-19 cases in our series, had been prescribed systemic steroids. Cumulative doses >600mg for prednisolone and 2-7 g of methylprednisolone predispose immunocompromised patients to mucormycosis. Though 63.3% of our patients had history of steroid administration, only six patients had received >600mg systemic prednisolone equivalent dose. Twenty-two cases, however, never received steroids but were diabetic. Thus steroids solely may not have contributed to the causation of ROCM. Further, Tocilizumab was administered in only two patients and had an unlikely role to play.

A large numbers of ROCM cases presenting over a short period of time during the second wave, similar to our study, indirectly points towards causal role of the new viral variant in ROCM. SARS-CoV-2 causes marked reduction in CD4+ and CD8+ T-cells, lowering the defence against invasive fungal infections. Airway epithelial damage in COVID-19 due to oxygen delivery devices, prolonged use of humidifiers without cleaning, use of industrial oxygen, multiple swab tests and steam inhalation burn injuries have been postulated to provide opportunity for fungus to invade lung tissues.
Contaminated oxygen as a possible source of infection was ruled out by Sen et al with 43% (1216 of 2818) of their CA-ROCM cases never being on oxygen support. In concurrence, in our series, only 50% (30/30) had received oxygen support and of the 3 cases treated in ICU, none had been on mechanical ventilation.

Ptosis was the commonest ocular manifestation, present in 29 of the 35 patients. Seven eyes having orbital apex syndrome with central retinal artery occlusion and 3 eyes with endophthalmitis had no light perception. Twelve eyes had diminution of vision due to branch retinal artery occlusion (1), exposure keratitis following facial palsy (3), endophthalmitis (1), optic atrophy (5) and immature senile cataract (2). Though ophthalmoplegia was seen in 23 eyes, only 2 patients complained of diplopia, the remaining 21 having ptosis or poor vision in the affected eye.

Lag between COVID-19 diagnosis and ROCM is reported to vary from 0 to 60 days, consistent with our findings. Detection of ROCM before 17 days (median value in our study) was seen in patients who had not received even a single dose of COVID-19 vaccine, had moderate COVID, had not been administered systemic steroids and had developed ocular or facial signs/symptoms. Ocular involvement especially vision loss or ptosis and facial signs is likely to alert the patient and physician earlier, leading to earlier detection of ROCM. The protection offered by the single dose of COVID-19 vaccination against ROCM is worth exploring as none of our patients had been fully immunized. In another report of 47 cases of ROCM from January 2 to March 27, 2021, 66% (31/47) had not been vaccinated. However, no definite explanation could be given for the causal relationship between early detection of ROCM, severity of COVID and oxygen therapy.

Aspergillus and candida are the commonly reported fungi with COVID-19 infection. In our series, mixed fungal infection was observed on histopathology in 3 of the 37 patients. Presentation of 58% cases beyond stage 2 ROCM, indicates the need for a high index of suspicion in COVID patients, especially with concurrent diabetes or immunocompromised status. The limitation of the study was the small sample size.

To conclude, the mutant COVID-19 variant in presence of glycaemic dysregulation predisposes to the development of ROCM.

Figure 3 Microbiological and histopathological features of mucorales. (A) KOH mount showing broad aseptate hyphae (yellow arrow). (B) Lactophenol cotton blue mount showing aseptate hyphae with extension of columella into sporangium (star). (C) Periodic acid Schiff stain (400x) showing broad aseptate hyphae with right angle branching (black arrowhead). (D) Silver methenamine stain (400×) showing broad aseptate hyphae (black arrowhead) in necrotic tissue.
of ROCM. Introduction of red flag signs of ROCM in the national guidelines for COVID management shall facilitate early diagnosis which is crucial for combating the mucor related morbidity and mortality.

**Abbreviations**

CA-ROCM, COVID-19 associated mucormycosis; HbA1c, Glycosylated haemoglobin.

**Disclosure**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

1. Menon S. India covid: how bad is the second wave? BBC News; May 7, 2021. Available from: https://www.bbc.com/news/56987209/. Accessed July 24, 2021.
2. Sen M. Black fungus: these two states account for nearly 42% of India’s 28,252 mucormycosis cases. Mint; June 7, 2021. Available from: https://www.livemint.com/news/india/black-fungus-28-states-see-28-252-mucormycosis-cases-maharashtra-gujarat-among-worst-hit-states-11623069135171.html. Accessed July 24, 2021.
3. Indian SARS-CoV-2 Genomics Consortium. Available from: https://dbtindia.gov.in/sites/default/files/Final%20MoHFW_Mutations%20in%20SARS-CoV2_NCDC_Final.pdf. Accessed 24 July, 2021.
4. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. *Diabetes Metab Syndr*. 2021;15(4):102146. doi:10.1016/j.dsx.2021.05.019
5. Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicentre study from Iran. *Mycoses*. 2021. doi:10.1111/myc.13334
6. Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), report 1. *Indian J Ophthalmol*. 2021;69(7):1670–1692. doi:10.4103/ijo.IJO_1565_21
7. Ramawami A, Sahu AK, Kumar A, et al. COVID-19 associated mucormycosis presenting to the emergency department - an Observational Study of 70 patients. *QJM*. 2021. doi:10.1093/qmed/hcab190
8. Honavar SG. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbital-cerebral mucormycosis in the setting of COVID-19. *Indian J Ophthalmol*. 2021;69(6):1361–1365. doi:10.4103/ijo.IJO_1156_21
9. Nabbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601–615. doi:10.1038/s41591-021-01283-z
10. Clinical management protocol for COVID-19 in adults. Available from: https://www.mohfw.gov.in/pdf/UpdatedDetailedClinicalManagementProtocolforCOVID19adultsdated24052021.pdf. Accessed July 24, 2021.
11. Petrikos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. *Clin Infect Dis*. 2012;54(Suppl 1):S23–S34. doi:10.1093/cid/cir866
12. Peterson KL, Wang M, Canalis RF, Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. *Laryngoscope*. 1997;107(7):855–862. doi:10.1097/00005537-199707000-00007
13. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. *Indian J Ophthalmol*. 2021;69(2):244–252. doi:10.4103/ijo.IJO_3774_20
14. Ismaiel WF, AbdElazim MH, Elsokyi I, et al. The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis. *Am J Otolaryngol*. 2021;42(6):103080. doi:10.1016/j.amjoto.2021.103080
15. Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: analysis of cases from 18 countries. *SSRN*. 2021. doi:10.2139/ssrn.3844587
16. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis*. 2005;41(5):634–653. doi:10.1086/432579
17. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: mucormycosis in COVID-19 times. *Indian J Ophthalmol*. 2021;69(6):1563–1568. doi:10.4103/ijo.IJO_310_21
18. Pal R, Bhadada SK, Misra A. Resurgence of COVID-19 and diabetes in India. *Diabetes Metab Syndr*. 2021;15(3):1037–1038. doi:10.1016/j.dsx.2021.04.024
19. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. *Lancet*. 2003;362(3938):1828–1838. doi:10.1016/S0140-6736(03)14904-5
20. Revannavar SM, P s S, Samaga L, V k V. COVID-19 triggering rhino-orbital-cerebral mucormycosis - an epidemic within a pandemic in India. *Lancet*. 2020;020-00462-9
21. Bhuyan A. Experts criticise India’s complacency over COVID-19. *Lancet*. 2021;397(10285):1611–1612. doi:10.1016/S0140-6736(21)00993-4
22. Gokulshankar S, Mohanty BK. COVID-19 and black fungus. *Asian J Med Health Sci*. 2021;4(1):138.
23. Brewster CT, Choong J, Thomas C, Wilson D, Moiemen N. Steam inhalation and paediatric burns during the COVID-19 pandemic. *Lancet*. 2020;395(10238):1690. doi:10.1016/S0140-6736(20)31144-2
24. Selarka L, Sharma S, Saini D, et al. Mucormycosis and COVID-19: an epidemic within a pandemic in India. *Mycoses*. 2021. doi:10.1111/mcy.13353
25. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. *Mycopathologia*. 2020;185(4):599–606. doi:10.1007/s11046-020-00462-9
